As was the case with ACLY, ACSS2 activity was a source of resistance to devimistat in AML cells, further highlighting the importance of alternative acetyl-CoA sources in the face of TCA cycle inhibition. This evidence concerns the gene ACSS2 and acute myeloid leukemia.